報價延遲最少15分鐘:2025/07/21 16:38 EDT
盤後時段
|
||||
|
26.17 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
26.17
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.76/-4.85
|
|
企業價值
775.65M
|
| 資產負債 |
|
每股賬面淨值
1.16
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
91.28M
|
|
每股收益
0.51
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/21 16:38 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
